Targeting Cancer: Microenvironment and Immunotherapy Innovations DOI Open Access
Irena Padzińska-Pruszyńska, Bartłomiej Taciak, Łukasz Kiraga

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13569 - 13569

Published: Dec. 18, 2024

In 2024, the United States was projected to experience 2 million new cancer diagnoses and approximately 611,720 cancer-related deaths, reflecting a broader global trend in which cases are anticipated exceed 35 by 2050. This increasing burden highlights ongoing challenges treatment despite significant advances that have reduced mortality 31% since 1991. Key obstacles include disease’s inherent heterogeneity complexity, such as resistance, stem cells, multifaceted tumor microenvironment (TME). The TME—comprising various immune blood vessels, biochemical factors—plays crucial role growth resistance therapies. Recent innovations treatment, particularly field of immuno-oncology, leveraged insights into TME interactions. An emerging example is FDA-approved therapy using tumor-infiltrating lymphocytes (TILs), demonstrating potential cell-based approaches solid tumors. However, TIL just one many strategies being explored. review provides comprehensive overview focusing on how novel therapies targeting or harnessing components could enhance efficacy address persistent care.

Language: Английский

The intricate dance of tumor evolution: Exploring immune escape, tumor migration, drug resistance, and treatment strategies DOI Creative Commons
Xiaojun Guo,

Xiaonan Bian,

Yitong Li

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1870(4), P. 167098 - 167098

Published: Feb. 25, 2024

Language: Английский

Citations

2
Exosomal microRNAs in lung cancer: a narrative review DOI Open Access
Zhe Zhang,

Fengwu Lin,

Wenqi Wu

et al.

Translational Cancer Research, Journal Year: 2024, Volume and Issue: 13(6), P. 3090 - 3105

Published: June 1, 2024

Exosomes are nanoscale extracellular vesicles secreted by cells, which can release bioactive macromolecules, such as microRNA (miRNA) to receptor cells. efficiently penetrate various biological barriers mediate intercellular communication. MiRNA a class of non-coding RNA that primarily regulate messenger (mRNA) at the post-transcriptional level. is abundant in exosomes, plays an important role being transported and released through exosomes lung cancer This review aims elucidate roles exosome-derived miRNAs cancer.

Language: Английский

Citations

2
Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma DOI Creative Commons

Longju Qi,

Shiyuan Chen,

Zehua Liao

et al.

Aging, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 27, 2024

Most cancers have a downregulation of Fidgetin (FIGN), which has been linked to tumor growth. However, there aren’t many papers that mention FIGN’s connection hepatocellular carcinoma (HCC). Here, FIGN expression in HCC tissues was markedly reduced as compared nearby normal liver tissues. According univariate and multivariate Cox regression, it served an independent predictor survival outcomes. Patients with high levels had worse outcome. shown be engaged immune-related pathways positive correlation immunological score immune cells according KEGG pathway analysis. In patients, substantially checkpoints the hot state. Additionally, immunotherapy chemotherapy showed significant therapeutic response patients low expression. This research revealed tightly related hepatoma immunity might employed biomarker predict patient prognosis guide medication.

Language: Английский

Citations

0
Editorial: Genetic and cellular heterogeneity in tumors DOI Creative Commons
Zishan Wang, Li Ma, Juan Xu

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: Dec. 9, 2024

occupying 10%-20% of invasive breast cancer cases, is the subtype with worst prognosis caused by absence targeted therapeutic options (Kumar and Aggarwal, 2016). Bone morphogenetic protein (BMP) signaling has been implicated in progression metastasis cancer, wherein high expression BMP8A revealed to be correlated poor survival (Katsuta et al., 2019). Sui al. investigated role TNBC, emphasizing its involvement bone metastasis. An elevated was observed TNBC cohort from TCGA, corroborated immunohistochemical staining experiment, associated patient's reduced survival. In vitro cellular function tests conducted cell lines, MDA-MB-231 BT549, demonstrated that overexpression accompanied invasion migration. Additionally, positively markers Epithelial-Mesenchymal Transition (EMT), a key processes facilitating tumor motility (Dongre Weinberg, 2019), Matrix Metalloproteinases (MMPs), which are thought affect behaviors including spread (Stamenkovic, 2003), suggesting may enhance invasiveness cells regulating EMT MMPs. The study correlation between biomarkers metastases, especially osteolytic factors RANKL, component RANK-RANKL-OPG system metabolism mammary epithelial development. Taken together, relevance metastasis, indicating potential TNBC.Metastatic accounts for more than 10% patients, leading cause death this population (Scully 2012;Esposito 2021). Similar reason such partly attributed lacking targetable genetic vulnerability While it believed only subset genetically predisposed metastasize, deeper insights into heterogeneity benefits personalized treatment metastatic (Basho Chase, 2023). Lake achieve at certain degree combing an organoidbased mice model digital droplet polymerase chain reaction (ddPCR) investigate genes whose copy number amplifications (CNA) identified Their methods focused on CNA FGFR1, most clinically mature targets their analysis. They found organoids display statistically significant amplification, demonstrating higher FGFR1 correlates organoid invasion. organoid-ddPCR provides robust method capture evaluate response, implications clinical practice biology.In addition heterogeneity, variations TME also influence outcomes (Desai 2024). Characterizing interactions distinct reveal critical vulnerabilities provide novel diagnostic perspectives (Li Han reviewed interplay myeloidderived suppressor (MDSCs) platelets, as well effects immune, metabolism, angiogenesis. MDSCs, known one effective immunosuppressive types, play roles strategy Tumor-associated platelets (TAPs) contribute immune evasion (Chen summarize existing preclinical studies, traditional Chinese medicine approaches, emerging technologies related targeting preventing interaction MDSCs TAPs TME, discussed mechanisms perspective future. Further investigation complexity side antiplatelet agent still required development.Given large impact types onto treatment, proposed score called leukemic stem (LSCA) predict acute myeloid leukemia (AML) patient terms expression-deconvoluted abundance TME. AML common type adults characterized immature differentiation (De Kouchkovsky Abdul-Hay, Leukemic (LSCs) major contributor drug resistance (Vetrie 2020;Zhai Jiang, 2022), but LSCs within remains inadequately investigated. Currently single analysis scale hematologic malignancy limited, expression-based prevalent. Thus, deconvolution informative forecasting prognosis. applied method, CIBERSORT (Newman 2015), hundreds samples inferred 9 cell-type fractions, subjected further feature selection. Five exhibiting significance estimate coefficients, granulocyte-monocyte progenitors (GMPs), (CMPs), CD45RA + (RApos), megakaryocyteerythrocyte (MEPs), multipotent (MPPs), were selected calculate LSC activity predicting LSCA successfully stratifies patients across cohorts, where lower scores showed favorable outcomes. area under curves (AUCs) indicated performance comparable prognostic models, LSC17 (Ng 2016), APS (Docking 2021), CTC (Dai utility tool tumor.This Research Topic valuable genetic-driven TME-driven tumor. Studies BMP8A's invasiveness, amplification MDSCplatelet development TME-cell-abundancebased all underscore importance research. These discoveries result advanced different technologies. rapidly evolving will gain genetic/TME finer resolution pave smooth way next generation

Language: Английский

Citations

0
Targeting Cancer: Microenvironment and Immunotherapy Innovations DOI Open Access
Irena Padzińska-Pruszyńska, Bartłomiej Taciak, Łukasz Kiraga

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13569 - 13569

Published: Dec. 18, 2024

In 2024, the United States was projected to experience 2 million new cancer diagnoses and approximately 611,720 cancer-related deaths, reflecting a broader global trend in which cases are anticipated exceed 35 by 2050. This increasing burden highlights ongoing challenges treatment despite significant advances that have reduced mortality 31% since 1991. Key obstacles include disease’s inherent heterogeneity complexity, such as resistance, stem cells, multifaceted tumor microenvironment (TME). The TME—comprising various immune blood vessels, biochemical factors—plays crucial role growth resistance therapies. Recent innovations treatment, particularly field of immuno-oncology, leveraged insights into TME interactions. An emerging example is FDA-approved therapy using tumor-infiltrating lymphocytes (TILs), demonstrating potential cell-based approaches solid tumors. However, TIL just one many strategies being explored. review provides comprehensive overview focusing on how novel therapies targeting or harnessing components could enhance efficacy address persistent care.

Language: Английский

Citations

0